Global Infrastructure for the Future of Advanced Therapies

Advanced therapies are transforming medicine, but the promise of innovation can only be realized if supply chains keep pace. Cell and gene therapies, regenerative medicines, and next-generation biotherapeutics require an integrated, end-to-end supply chain infrastructure built to scale globally.

Cryoport Systems is meeting that challenge through our expanding network of Global Supply Chain Centers. These multi-service hubs combine various services like cryopreservation, BioServices and biostorage, logistics, and consulting and ad-visory services under one roof, reducing handoffs and eliminating fragmentation. Each center is strategically located within major life sciences regions, giving spon-sors proximity to patients, manufacturing sites, and trial networks while ensuring consistency through standardized processes and global quality frameworks.

Our established Global Supply Chain Centers in Houston, Texas and Morris Plains, New Jersey already support some of the most complex programs in the world. By late 2025, our new Paris, France facility will join this network, strengthening sup-port for clinical and commercial programs across Europe. A second new center in Santa Ana, California, will follow in 2026. These Global Supply Chain Centers join our greater network of logistics facilities, cryopreservation facilities, and BioSer-vices facilities to provide comprehensive access around the world.

Partnering with Cryoport Systems offers sponsors more than infrastructure. You gain a trusted partner able to manage every stage, from collection kits and cryopreservation of leukapheresis-derived starting materials to global logistics, regulatory support, and fi nal patient delivery. Backed by the industry’s largest wholly owned fl eet of shipping systems, proprietary quality standards, and true global reach, our platform delivers not just materials, but outcomes.

Because innovation can only change lives if it can reach them.